Evaluation of Neutrophil to Lymphocyte (NLR),Platelet to lymphocyte (PLR) and Lymphocyte to Monocyte (LMR) ratios in peripheral blood of patients having periodontitis with type 2 diabetes mellitus before and one month after scaling and root planing - NI

Dr. Nikita Vikasrao Palkar0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1.Subjects with clinically healthy periodontium, with no attachment loss and probing depth of less than or equal to 3 mm, <10%bleeding sites, subject with gingival index score of maximum up to <1, included which were considered to be relatively healthy and subject having HbA1c level between 4%–6% considered as control group.
•2.Group B:
•1.Patients with Periodontitis stage II and stage III as per the 2017 American Academy of Periodontology Classification.
•2.Patients with periodontitis stage II having clinical attachment loss of 3-4mm and maximum probing pocket depth =5 mm.
•3.Patients with periodontitis stage III having clinical attachment loss of =5 mm and maximum probing pocket depth = 6mm.35
•3.Group C:
•1.Patients with periodontitis (stage II and stage III as per the 2017 American Academy of Periodontology classification) with diagnosed case of type 2 diabetes mellitus (Good diabetes control, HbA1c level 7%)

•1.Patient refusal
•2.Patient who has received periodontal treatment in last 6months.
•3.Patient who is smoker or consuming any other form of tobacco.
•4.Pregnant, lactating or postmenopausal women.
•5.Hospitalized patients.
•6.Subjects consuming antibiotic or other drugs in the past 6 months that affect their periodontal status.
•7.History of any systemic disease which influences the values of NLR, PLR, and LMR ratio like any malignancy, cardiovascular diseases, rheumatic diseases, bipolar disorder, thyrotoxicosis, psoriasis other than type 2 diabetes mellitus for the test group (Group III)
•8.History of any systemic disease for the control group.
•9.If subject cannot maintain oral hygiene after non-surgical periodontal therapy (Gingival index score >1, plaque index >1).

发起方

Dr. Nikita Vikasrao Palkar